Assertio Holdings, Inc. reported its fourth‑quarter and full‑year 2025 financial results on March 16, 2026. The company posted Q4 revenue of $13.54 million, a 54 % decline from the $28.36 million consensus estimate and a 53 % drop from the $29.6 million recorded in Q4 2024. Earnings per share were $‑1.06, missing the $‑0.07 estimate by 1414 % and falling short of the $‑1.80 and $‑3.05 estimates cited in other analyst reports. Full‑year revenue reached $117.1 million, down 2.4 % from the $120.8 million reported in 2024, while full‑year EPS was $‑1.06 versus $‑0.07 expected.
The decline in revenue was largely driven by the timing of channel inventory associated with the Rolvedon sell‑in. In Q4, Rolvedon sales were $0.4 million compared with $15.4 million in Q4 2024, while full‑year Rolvedon revenue rose to $68.2 million from $60.1 million in 2024. Gross margin improved to 75 % in Q4 from 61 % in Q4 2024, and 70 % for the full year versus 68 % in 2024, reflecting a higher mix of high‑margin Indocin sales and the absence of prior‑year inventory write‑downs. SG&A expenses fell to $13.1 million from $21.4 million in the prior year, driven by lower legal costs after litigation initiatives and reduced personnel expenses following restructuring.
Management highlighted the strategic shift away from acquiring on‑market specialty products. CEO Mark L. Reisenauer said, "our prior strategy of acquiring on‑market specialty products is no longer capital efficient or a sustainable strategy to fuel growth." He added, "The plan would be to continue to focus on the community Medicare Part B setting," and noted that the integration of Rolvedon is now complete and the company is poised to commence regular sales of its newly labeled version by the second quarter of 2026. CFO Ajay Patel explained the revenue decline: "Total product sales in the fourth quarter were $12.8 million compared to $29.6 million in the prior year, primarily driven by the timing of channel inventory associated with the previously disclosed Rolvedon sell‑in." He also said, "Gross margin improved to 75% compared to 61% in the prior year," and "Reported SG&A expenses were $13.1 million, down from $21.4 million in the prior year, reflecting lower legal expenses following completion of litigation‑related initiatives as well as reduced personnel costs following restructuring actions taken in the fourth quarter." COO Paul Schwichtenberg emphasized commercial realignment: "optimize cash flow from our tail assets while continuing to support the growth of Rolvedon," and added, "we expect that the quarterly demand will be generally align with the quarterly shipments in 2026."
Guidance for fiscal 2026 reflects confidence in a rebound. Assertio set revenue guidance of $110 million to $125 million and adjusted EBITDA guidance of $28 million to $40 million, up from the prior year’s $110 million to $125 million and $28 million to $40 million range, respectively. The company’s forward outlook is anchored by the expected regular sales of Rolvedon beginning in Q2 2026 and the continued focus on its community oncology platform.
Market reaction was positive despite the earnings miss. The stock closed at $11.54, up 2.08 % in post‑market trading on March 16, 2026. Investors appeared to value the improved gross margins, reduced SG&A, and the forward guidance that signals a recovery driven by Rolvedon, offsetting the short‑term revenue and EPS shortfall.
The reverse stock split completed on December 26, 2025, consolidated 15 shares into one to maintain Nasdaq listing compliance, but did not materially affect the company’s financial performance or outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.